Safety and Efficacy of Emixustat in Stargardt Disease

 Stargardt Disease 1 / Posted 11 months ago

The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease.

  • Study start date : 01/11/2018
  • Study end date : 01/02/2022
  • Wales-Based Study Contact : please speak to your clinician
Contact details

Moorfields Eye Hospital NHS Foundation Trust London EC1V 2PD Oxford Eye Hospital,Oxford University Hospitals NHS Foundation Trust Oxford Oxfordshire OXD3 9DUEngland  Show Phone Number ClinicalTrials@acucela.com bepartofresearch.nihr.ac.uk

No post found